Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.54 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.50 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.50 |
| ▸ | CDC7 | O00311 | 9/20 | 0.49 |
| ▸ | PIM1 | P11309 | 9/20 | 0.49 |
| ▸ | PRKACA | P17612 | 9/20 | 0.49 |
| ▸ | GSK3B | P49841 | 9/20 | 0.49 |
| ▸ | HIPK2 | Q9H2X6 | 9/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 8/20 | 0.49 |
| ▸ | CDK2 | P24941 | 8/20 | 0.49 |
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 6/20 | 0.49 |
| ▸ | CLK4 | Q9HAZ1 | 5/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 7/20 | 0.48 |
| ▸ | DAPK3 | O43293 | 4/20 | 0.48 |
| ▸ | FLT3 | P36888 | 4/20 | 0.48 |
| ▸ | CLK2 | P49760 | 4/20 | 0.48 |
| ▸ | CDK7 | P50613 | 4/20 | 0.48 |
| ▸ | CDK9 | P50750 | 4/20 | 0.48 |
| ▸ | PRKX | P51817 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19823045 | 0.82 | TNIK (0.54) | CAMKK2DYRK1BTNIKCDC7PIM1 | |
| SCHEMBL14620845 | 0.80 | CAMKK2 (0.62) | CAMKK2DYRK1BCDC7PIM1PRKACA | |
| SCHEMBL19823067 | 0.79 | TNIK (0.68) | TNIKROCK2CDK2FLT3ROCK1 | |
| SCHEMBL19823044 | 0.79 | LRRK2 (0.59) | CAMKK2TNIKCDC7CDK2DYRK1A | |
| SCHEMBL858766 | 0.78 | CAMKK2 (0.64) | CAMKK2DYRK1BCDC7PIM1PRKACA | |
| SCHEMBL19823109 | 0.78 | TNIK (0.53) | CAMKK2TNIKCDC7PIM1PRKACA | |
| SCHEMBL19823047 | 0.77 | TNIK (0.49) | CAMKK2DYRK1BTNIKCDC7PIM1 | |
| SCHEMBL19823048 | 0.77 | TNIK (0.52) | CAMKK2TNIKJAK2 | |
| SCHEMBL857135 | 0.77 | CAMKK2 (0.56) | CAMKK2DYRK1BCDC7PIM1PRKACA | |
| SCHEMBL858447 | 0.77 | CAMKK2 (0.56) | CAMKK2DYRK1BCDC7PIM1PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11279699-B2 | Compound as selective JAK inhibitor, and salt and therapeutic use thereof | SUZHOU LONGBIOTECH PHARMACEUTICALS CO., LTD. (CN) | 2022-03-22 | — | — | US | claimed |
| US-20200190080-A1 | COMPOUND AS SELECTIVE JAK INHIBITOR, AND SALT AND THERAPEUTIC USE THEREOF | TIANJIN LONGBOGENE PHARMACEUTICAL CO., LTD. (CN) | 2020-06-18 | — | — | US | claimed |
| EP-3492469-A1 | COMPOUND AS SELECTIVE JAK INHIBITOR, AND SALT AND THERAPEUTIC USE THEREOF | Tianjin Longbogene Pharmaceutical Co., Ltd. (CN) | 2019-06-05 | — | — | EP | claimed |
| CN-109843883-A | Alternatively property JAK inhibitor compound, the salt and its therapeutical uses of the compound | 天津隆博基因药物科技有限公司 | 2019-06-04 | — | — | CN | claimed |
| US-11279699-B2 | Compound as selective JAK inhibitor, and salt and therapeutic use thereof | SUZHOU LONGBIOTECH PHARMACEUTICALS CO., LTD. (CN) | 2022-03-22 | — | — | US | disclosed |
| CN-109843883-B | Compounds as selective JAK inhibitors, salts of the compounds and therapeutic uses thereof | 苏州隆博泰药业有限公司 | 2022-01-14 | — | — | CN | disclosed |
| EP-3492469-B1 | COMPOUND AS SELECTIVE JAK INHIBITOR, AND SALT AND THERAPEUTIC USE THEREOF | SUZHOU LONGBIOTECH PHARMACEUTICALS CO LTD (CN) | 2021-12-01 | — | — | EP | disclosed |
| US-20200190080-A1 | COMPOUND AS SELECTIVE JAK INHIBITOR, AND SALT AND THERAPEUTIC USE THEREOF | TIANJIN LONGBOGENE PHARMACEUTICAL CO., LTD. (CN) | 2020-06-18 | — | — | US | disclosed |
| EP-3492469-A1 | COMPOUND AS SELECTIVE JAK INHIBITOR, AND SALT AND THERAPEUTIC USE THEREOF | Tianjin Longbogene Pharmaceutical Co., Ltd. (CN) | 2019-06-05 | — | — | EP | disclosed |
| CN-109843883-A | Alternatively property JAK inhibitor compound, the salt and its therapeutical uses of the compound | 天津隆博基因药物科技有限公司 | 2019-06-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190080-A1 | COMPOUND AS SELECTIVE JAK INHIBITOR, AND SALT AND THERAPEUTIC USE THEREOF | JAK1, JAK2, JAK3 | CAMKK2 989/4885DYRK1B 466/4885TNIK 397/4885 |
| US-11279699-B2 | Compound as selective JAK inhibitor, and salt and therapeutic use thereof | JAK1, JAK2, JAK3 | CAMKK2 989/4885DYRK1B 466/4885TNIK 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.